Neurol. praxi. 2017;18(3):208-211 | DOI: 10.36290/neu.2019.069

Perampanel – what to do with it?

prof. MUDr. Ivan Rektor, CSc.,, MUDr. Ondřej Strýček

Masarykova Univerzita, Centrum pro epilepsie Brno, 1. neurologická klinika LF MU ve FN u sv. Anny, Brno

CEITEC – Středoevropský technologický institut, Centrum neurověd, Brno

Fycompa® (perampanel – PER) is new antiepileptic drug with a specific mechanism of action, different from other drugs. It is well tolerated

and its safety profile is favourable with minimum of adverse effects, which are mild to moderate intensity even in high doses.

Its interactive potential is low and allow combined therapy with other antiepileptic drugs. Great advantage are perampanel pharmacokinetic

characteristics, offering the convenience of once- daily administration. It is effective add-on therapy of focal epilepsy and

primary generalized tonic-clonic seizures in idiopathic generalised epilepsy. Many open label extension studies proved its efficacy

even on generalized seizures (primary or secondary). Its pharmacological characteristics, good tolerability and high efficacy in focal and

generalized epilepsies make perampanel promising drug in seizure freedom reaching and so reduce the risks associated with seizures.

Keywords: epilepsy, treatment, seizure freedom, AMPA receptor, perampanel

Received: September 26, 2019; Accepted: September 27, 2019; Prepublished online: September 27, 2019; Published: July 1, 2017  Show citation